| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NUVB | Class A Common Stock | Purchase | $262K | +87.7K | +5.24% | $2.99 | 1.76M | Jun 20, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP | F1, F2 |
| transaction | NUVB | Class A Common Stock | Purchase | $226K | +75.4K | +4.28% | $3.00 | 1.84M | Jun 21, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP | F2, F3 |
| transaction | NUVB | Class A Common Stock | Purchase | $1M | +337K | +18.32% | $2.98 | 2.18M | Jun 24, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP | F2, F4 |
| holding | NUVB | Class A Common Stock | 314K | Jun 20, 2024 | By Decheng Capital China Life Sciences USD Fund III, L.P. | F5 | |||||
| holding | NUVB | Class A Common Stock | 4.18M | Jun 20, 2024 | By Decheng Anbio Limited | F6 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F2 | These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F5 | These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| F6 | These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |